Antibody Response against SARS-CoV-2 Infection: Implications for Diagnosis, Treatment and Vaccine Development

References

• de Alwis R, Chen S, Gan ES, Ooi EE. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine. 2020;55:102768. https://doi.org/https://doi.org/10.1016/j.ebiom.2020.102768.
   PubMed Web of Science ®Google Scholar
• Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564–1581. https://doi.org/https://doi.org/10.1111/all.14364.
   PubMed Web of Science ®Google Scholar
• Ni L, Ye F, Cheng ML, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020;52(6):971–977.e3. https://doi.org/https://doi.org/10.1016/j.immuni.2020.04.023.
   PubMed Web of Science ®Google Scholar
• Padoan A, Sciacovelli L, Basso D, et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. Clin Chim Acta. 2020;507:164–166. https://doi.org/https://doi.org/10.1016/j.cca.2020.04.026.
   PubMed Web of Science ®Google Scholar
• De Campos Mata L, Piñero J, Vaquero ST, et al. SARS-CoV-2-specific antibody profiles distinguish patients with moderate from severe COVID-19. medRxiv 2020.12.18.20248461. https://doi.org/https://doi.org/10.1101/2020.12.18.20248461.
   Google Scholar
• Rijkers G, Murk JL, Wintermans B, et al. Differences in antibody kinetics and functionality between severe and mild SARS-CoV-2 infections. J Infect Dis. 2020;222(8):1265–1269. https://doi.org/https://doi.org/10.1093/infdis/jiaa463.
   PubMed Web of Science ®Google Scholar
• Lynch KL, Whitman JD, Lacanienta NP, et al. Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity. Clin Infect Dis. 2021;72(2):301–308. https://doi.org/https://doi.org/10.1093/cid/ciaa979.
   PubMed Web of Science ®Google Scholar
• Carnicelli AFiori B, Ricci R, et al. Characteristic of IgA and IgG antibody response to SARS-CoV-2 infection in an Italian referral Covid-19 hospital. medRxiv 2020.11.16.20232470. https://doi.org/https://doi.org/10.1101/2020.11.16.20232470.
   Google Scholar
• Tan W, Lu Y, Zhanget J, et al. Viral kinetics and antibody responses in patients with COVID-19medRxiv 2020. https://doi.org/https://doi.org/10.1101/2020.03.24.20042382.
   Google Scholar
• Sun B, Feng Y, Mo X, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microb Infect. 2020;9(1):940–948. https://doi.org/https://doi.org/10.1080/22221751.2020.1762515.
   PubMed Web of Science ®Google Scholar
• Atyeo C, Fischinger S, Zohar T, et al. Distinct early serological signatures track with SARS-CoV-2 survival. Immunity. 2020;1553(3):524–532.e4. https://doi.org/https://doi.org/10.1016/j.immuni.2020.07.020.
   PubMed Web of Science ®Google Scholar
• Xiao T, Wang Y, Yuan J, et al. Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers. Front Med (Lausanne). 2021;8:595773. https://doi.org/https://doi.org/10.3389/fmed.2021.595773.
   PubMed Web of Science ®Google Scholar
• Long Q, Deng H, Chenet J, et al. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. medRxiv. 2020; https://doi.org/https://doi.org/10.1101/2020.03.18.20038018.
   Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Coyle P, et al. ARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks. medRxiv 2021.01.15.21249731. https://doi.org/https://doi.org/10.1101/2021.01.15.21249731.
   Google Scholar
• Tan Y, Liu F, Xu X, et al. Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. Front Med. 2020;14(6):746–751. https://doi.org/https://doi.org/10.1007/s11684-020-0822-5.
   PubMed Web of Science ®Google Scholar
• Crawford KHD, Dingens AS, Eguia R, at al. Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection. J Infect Dis. 2021;223(2):197–205. https://doi.org/https://doi.org/10.1093/infdis/jiaa618.
   PubMed Web of Science ®Google Scholar
• Phipps WS, SoRelle JA, Li QZ, et al. SARS-CoV-2 antibody responses do not predict COVID-19 disease severity. Am J Clin Pathol. 2020;154(4):459–465. https://doi.org/https://doi.org/10.1093/ajcp/aqaa123.
   PubMed Web of Science ®Google Scholar
• Suthar MS, Zimmerman MG, Kauffman RC, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med. 2020;1(3):100040. https://doi.org/https://doi.org/10.1016/j.xcrm.2020.100040.
   PubMedGoogle Scholar
• Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52):eabe0367. https://doi.org/https://doi.org/10.1126/sciimmunol.abe0367.
   PubMed Web of Science ®Google Scholar
• Yongchen Z, Shen H, Wang X, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. Emerg Microb Infect. 2020;9(1):833–836. https://doi.org/https://doi.org/10.1080/22221751.2020.1756699.
   PubMed Web of Science ®Google Scholar
• Wu F, Wang A, Liuet M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv 2020. https://doi.org/https://doi.org/10.1101/2020.03.30.20047365
   Google Scholar
• Kuri-Cervantes L, Pampena MB, Meng W, et al. Immunologic perturbations in severe COVID-19/SARS-CoV-2 infection. Preprint. bioRxiv. 2020;2020.05.18.101717. Published 2020 May 18. https://doi.org/https://doi.org/10.1101/2020.05.18.101717.
   Google Scholar
• Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. Nature. 2020;584:437–442. https://doi.org/https://doi.org/10.1038/s41586-020-2456-9.
   PubMed Web of Science ®Google Scholar
• Brouwer PJM, Caniels TG, van der Straten K, et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369(6504):643–650. https://doi.org/https://doi.org/10.1126/science.abc5902.
   PubMed Web of Science ®Google Scholar
• Rogers TF, Zhao F, Huang D, et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020;369(6506):956–963. https://doi.org/https://doi.org/10.1126/science.abc7520.
   PubMed Web of Science ®Google Scholar
• Zost SJ, Gilchuk P, Case JB, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020;584(7821):443–449. https://doi.org/https://doi.org/10.1038/s41586-020-2548-6[32668443]
   PubMed Web of Science ®Google Scholar
• Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. bioRxiv [Preprint]. 2021; Update in: Nat Med. 2021 Mar 2; PMID: 33501446; PMCID: PMC7836116.
   Google Scholar
• Ruetalo N, Businger R, Althauset K, al. Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients. medRxiv 2020.08.07.20169961. https://doi.org/https://doi.org/10.1101/2020.08.07.20169961.
   Google Scholar
• Okba NMA, Müller MA, Li W, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020;26(7):1478–1488. https://doi.org/https://doi.org/10.3201/eid2607.200841.
   PubMed Web of Science ®Google Scholar
• Legros V, Denolly S, Vogrig M, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021;18(2):318–327. https://doi.org/https://doi.org/10.1038/s41423-020-00588-2.
   PubMed Web of Science ®Google Scholar
• Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020;71(15):778–785. https://doi.org/https://doi.org/10.1093/cid/ciaa310.
   PubMed Web of Science ®Google Scholar
• Burbelo PD, Riedo FX, Morishima C, et al. Sensitivity in detection of antibodies to nucleocapsid and spike proteins of severe acute respiratory syndrome coronavirus 2 in patients with coronavirus disease 2019. J Infect Dis. 2020;222(2):206–213. https://doi.org/https://doi.org/10.1093/infdis/jiaa273[32427334].
   PubMed Web of Science ®Google Scholar
• Okba N, Müller MA, Li W, et al. SARS-CoV-2 specific antibody responses in COVID-19 patients. Emerg Infect Dis. 2020;26(7):1478–1488. https://doi.org/https://doi.org/10.3201/eid2607.200841.
   PubMed Web of Science ®Google Scholar
• Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. The role of antibody testing for SARS-CoV-2: is there one?J Clin Microbiol. 2020;58(8):e00797–20. Published 2020 Jul 23. https://doi.org/https://doi.org/10.1128/JCM.00797-20.
   PubMed Web of Science ®Google Scholar
• Ng KW, Faulkner N, Cornish GH, et al. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans. Science. 2020;370(6522):1339–1343. https://doi.org/https://doi.org/10.1126/science.abe1107.
   PubMed Web of Science ®Google Scholar
• Morgenlander W, Henson S, Monaco D, et al. Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. medRxiv 2020.12.16.20248294. https://doi.org/https://doi.org/10.1101/2020.12.16.20248294.
   Google Scholar
• Yan G, Lee CK, Lam LTM, et al. Covert COVID-19 and false-positive dengue serology in Singapore. Lancet Infect Dis. 2020;20(5):536. https://doi.org/https://doi.org/10.1016/S1473-3099(20)30158-4.
   PubMed Web of Science ®Google Scholar
• Nath H, Mallick A, Roy S, et al. Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity?Comput Struct Biotechnol J. 2021;19:459–466. https://doi.org/https://doi.org/10.1016/j.csbj.2020.12.037.
   PubMed Web of Science ®Google Scholar
• Lee CY, Lin RTP, Renia L, Ng LFP. Serological approaches for COVID-19: epidemiologic perspective on surveillance and control. Front Immunol. 2020;11:879. Published. 2020;11:879. https://doi.org/https://doi.org/10.3389/fimmu.2020.00879.
   PubMed Web of Science ®Google Scholar
• Salazar E, Kuchipudi SV, Christensen PA, et al. Relationship between anti-spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma. Preprint. bioRxiv. 2020;2020.06.08.138990. Published 2020 Jun 9. https://doi.org/https://doi.org/10.1101/2020.06.08.138990.
   Google Scholar
• Bao L, Deng W, Gao H, et al. Lack of reinfection in rhesus macaques infected with SARS-CoV-2. bioRxiv 2020. https://doi.org/https://doi.org/10.1101/2020.03.13.990226.
   Google Scholar
• Wu LP, Wang NC, Chang YH, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562–1564. https://doi.org/https://doi.org/10.3201/eid1310.070576.
   PubMed Web of Science ®Google Scholar
• Payne DC, Iblan I, Rha B, et al. Persistence of antibodies against middle east respiratory syndrome coronavirus. Emerg Infect Dis. 2016;22(10):1824–1826. .
   PubMed Web of Science ®Google Scholar
• Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545–1548. https://doi.org/https://doi.org/10.1172/JCI138003.
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Goldman M, Vincent JL. Antibody-based therapies for COVID-19: can Europe move faster? PLoS Med. 2020;17(5):e1003127. Published 2020 May 5. https://doi.org/https://doi.org/10.1371/journal.pmed.1003127.
   PubMed Web of Science ®Google Scholar
• Kumar S, Sharma V, Priya K. Battle against COVID-19: efficacy of convalescent plasma as an emergency therapy. Am J Emerg Med. 2021;41:244–246. https://doi.org/https://doi.org/10.1016/j.ajem.2020.05.101.
   PubMed Web of Science ®Google Scholar
• US Food and Drug administration (FDA). Expanded Access Program, Version 10.0. https://www.uscovidplasma.org/pdf/COVID-19%20Plasma%20EAP.pdf. Published August 3, 2020.
   Google Scholar
• Barone P, DeSimone RA. Convalescent plasma to treat coronavirus disease 2019 (COVID-19): considerations for clinical trial design. Transfusion. 2020;60(6):1123–1127. https://doi.org/https://doi.org/10.1111/trf.15843.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Mukherjee A, Kumar G.et al. Convalescent plasma in the management of moderate COVID-19 in India: An open-label parallel-arm phase II multicentre randomized controlled trial (PLACID Trial). Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371:m3939. https://doi.org/https://doi.org/10.1136/bmj.m3939. Erratum in: BMJ. 2020 Nov 3;371:m4232.
   Google Scholar
• Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv 2020.08.12.20169359. https://doi.org/https://doi.org/10.1101/2020.08.12.20169359.
   Google Scholar
• Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610–618. https://doi.org/https://doi.org/10.1056/NEJMoa2033700.
   PubMed Web of Science ®Google Scholar
• Shenoy AG, Hettinger AZ, Fernandez SJ, et al. Early mortality benefit with COVID-19 convalescent plasma: a matched control study. Br J Haematol. 2021;192(4):706–713. Epub 2021 Jan 22. https://doi.org/https://doi.org/10.1111/bjh.17272.
   PubMed Web of Science ®Google Scholar
• Eroshenko N, Gill T, Keaveney MK, et al. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nat Biotechnol. 2020;38(7):789–791. https://doi.org/https://doi.org/10.1038/s41587-020-0577-1. PMID: 32504046.
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. 2020;20(6):339–341. https://doi.org/https://doi.org/10.1038/s41577-020-0321-6.
   PubMed Web of Science ®Google Scholar
• Joyner M, Scott Wright R, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. Preprint. medRxiv. 2020;2020.05.12.20099879. Published 2020 May 14. https://doi.org/https://doi.org/10.1101/2020.05.12.20099879.
   Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470. https://doi.org/https://doi.org/10.1001/jama.2020.10044. Erratum in: JAMA. 20204;324(5):519.
   Google Scholar
• Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323(16):1561–1562. https://doi.org/https://doi.org/10.1001/jama.2020.4940. PMID: 32219429.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Xie YW, Hong J, et al. Purification of severe acute respiratory syndrome hyperimmune globulins for intravenous injection from convalescent plasma. Transfusion. 2005;45(7):1160–1164. https://doi.org/https://doi.org/10.1111/j.1537-2995.2005.00179.x.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. https://doi.org/https://doi.org/10.1126/science.abb2507.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281–292.e6. https://doi.org/https://doi.org/10.1016/j.cell.2020.02.058.
   PubMed Web of Science ®Google Scholar
• Tian X, Li C, Huang A, et al. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microb Infect. 2020;9(1):382–385. Published 2020 Feb 17. https://doi.org/https://doi.org/10.1080/22221751.2020.1729069.
   PubMed Web of Science ®Google Scholar
• Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368(6491):630–633. https://doi.org/https://doi.org/10.1126/science.abb7269.
   PubMed Web of Science ®Google Scholar
• Pinto D, Park YJ, Beltramello M, et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–295. https://doi.org/https://doi.org/10.1038/s41586-020-2349-y.
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection [published correction appears in Nat Commun. 2020 May 14;11(1):2511]. Nat Commun. 2020;11(1):2251. Published 2020 May 4. https://doi.org/https://doi.org/10.1038/s41467-020-16256-y.
   PubMed Web of Science ®Google Scholar
• Jones BE, Brown-Augsburger PL, Corbett KS, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv 2020.09.30.318972. https://doi.org/https://doi.org/10.1101/2020.09.30.318972.
   Google Scholar
• Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–124. https://doi.org/https://doi.org/10.1038/s41586-020-2381-y.
   PubMed Web of Science ®Google Scholar
• Hansen J, Baum A, Pascal KE, et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science. 2020;369(6506):1010–1014. https://doi.org/https://doi.org/10.1126/science.abd0827.
   PubMed Web of Science ®Google Scholar
• Cao Y, Su B, Guo X, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients’ B cells. Cell. 2020;182(1):73–84.e16. https://doi.org/https://doi.org/10.1016/j.cell.2020.05.025.
   PubMed Web of Science ®Google Scholar
• Miersch S, Ustav M, Liet Z, et al. Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells. bioRxiv. https://doi.org/https://doi.org/10.1101/2020.06.05.137349.
   Google Scholar
• Gai J, Ma L, Li G, et al. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential. MedComm (Beijing). 2021;2(1):101–113. https://doi.org/https://doi.org/10.1002/mco2.60.
   PubMedGoogle Scholar
• Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682–687. https://doi.org/https://doi.org/10.1038/s41586-020-2852-1. Epub 2020 Oct 12. PMID: 33045718.
   PubMed Web of Science ®Google Scholar
• Wu Y, Li C, Xia S, et al. Identification of human single-domain antibodies against SARS-CoV-2. Cell Host Microbe. 2020;27(6):891–898.e5. https://doi.org/https://doi.org/10.1016/j.chom.2020.04.023.
   PubMed Web of Science ®Google Scholar
• Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650–655. Epub 2020 Jun 22. https://doi.org/https://doi.org/10.1126/science.abc6952.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020;584:450–456. https://doi.org/https://doi.org/10.1038/s41586-020-2571-7.
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–644. https://doi.org/https://doi.org/10.1001/jama.2021.0202.
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384(3):238–251. https://doi.org/https://doi.org/10.1056/NEJMoa2035002.
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–135. https://doi.org/https://doi.org/10.1038/s41586-021-03398-2. Epub 2021 Mar 8. PMID: 33684923.
   PubMed Web of Science ®Google Scholar
• De Gasparo R, Pedotti M, Simonelli L, et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 2021;593(7859):424–428. https://doi.org/https://doi.org/10.1038/s41586-021-03461-y. Epub 2021 Mar 25. PMID: 33767445.
   PubMed Web of Science ®Google Scholar
• European Medicines agencies website: https://www.ema.europa.eu/en/human-regulatory/overview/public-healththreats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines.
   Google Scholar
• Tumban E. Lead SARS-CoV-2 candidate vaccines: expectations from phase III trials and recommendations post-vaccine approval. Viruses. 2021;13(1):54. Published online 2020 Dec 31. https://doi.org/https://doi.org/10.3390/v13010054.
   Web of Science ®Google Scholar
• Ura T, Yamashita A, Mizuki N, et al. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine. 2021;39(2):197–201. https://doi.org/https://doi.org/10.1016/j.vaccine.2020.11.054. Epub 2020 Nov 24.
   PubMed Web of Science ®Google Scholar
• Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021;397(10278):1023–1034. Published online 2021 Feb 12. https://doi.org/https://doi.org/10.1016/S0140-6736(21)00306-8.
   PubMed Web of Science ®Google Scholar
• Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. Epub 2020 Oct 15. https://doi.org/https://doi.org/10.1016/S1473-3099(20)30831-8.
   PubMed Web of Science ®Google Scholar
• Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. bioRxiv 2021.01.15.426911. https://doi.org/https://doi.org/10.1101/2021.01.15.426911.
   Google Scholar
• Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv 2021.01.25.427948. https://doi.org/https://doi.org/10.1101/2021.01.25.427948.
   Google Scholar
• Edara VV, Norwood C, Floyd K, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microb. 2021;29(4):516–521.e3. https://doi.org/https://doi.org/10.1016/j.chom.2021.03.009.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu J, Xia H, et al. Neutralizing activity of BNT162b2-elicited serum. N Engl J Med. 2021;384(15):1466–1468. https://doi.org/https://doi.org/10.1056/NEJMc2102017.
   PubMed Web of Science ®Google Scholar
• Stamatatos L, Czartoski J, Wan YH, et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 25:eabg9175. https://doi.org/https://doi.org/10.1126/science.abg9175. Epub ahead of print. PMID: 33766944.
   Google Scholar
• Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. Mucosal immunity in COVID-19: a neglected but critical aspect of SARS-CoV-2 infection. Front Immunol. 2020;11:611337. https://doi.org/https://doi.org/10.3389/fimmu.2020.611337.
   PubMed Web of Science ®Google Scholar
• Verdecchia P, Cavallini C, Spanevello A, Angeli F. COVID-19: ACE2centric Infective Disease?Hypertension. 2020 Aug;76(2):294–299. https://doi.org/https://doi.org/10.1161/HYPERTENSIONAHA.120.15353. Epub 2020 Jun 1. PMID: 32476472.
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5):e02015–19. Published 2020 Feb 14. https://doi.org/https://doi.org/10.1128/JVI.02015-19.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang L, Kuwahara K, et al. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates [published correction appears in ACS Infect Dis. 2020 May 8;6(5):1284-1285]. ACS Infect Dis. 2016;2(5):361–376. https://doi.org/https://doi.org/10.1021/acsinfecdis.6b00006.
   PubMed Web of Science ®Google Scholar